| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
22,870,000 |
| Market
Cap: |
13.13(M) |
| Last
Volume: |
10,099 |
Avg
Vol: |
2,697 |
| 52
Week Range: |
$0.496 - $3.29 |
|
| Level
I Sector: |
Financials |
| Level
II Sector: |
Financial Services |
| Level
III Sector: |
Investment Brokerage - Regional |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ OTHER FINANCE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile VBI Vaccines is a biopharmaceutical company. Co. develops vaccine candidates that mimic the natural presentation of viruses. Co.'s pipeline is comprised of vaccine and immunotherapeutic candidates developed by virus-like particle technologies to target two disease areas, infectious disease and oncology. Co.'s prophylactic candidates are 3-antigen Vaccine for the indication of Hepatitis B (HBV), VBI-1501 for the indication of Cytomegalovirus (CMV), VBI-2901 for the indication of Pan-coronavirus, and VBI-2902 for the indication of COVID-19. Co.'s therapeutic candidates are VBI-2601 for the indication of HBV and VBI-1901 for the indication of Glioblastoma plus other CMV-Associated Cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gillis Steven |
Director |
– • – |
2019-09-19 |
4 |
B |
$0.50 |
$5,000,000 |
I/I |
10,000,000 |
13,026,057 |
2.1 |
- |
|
| Dewilde Michel |
Director |
– • – |
2016-12-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,500 |
|
- |
|
| Baxter Jeff |
President and CEOOfficer |
• • – |
2016-12-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
69,005 |
|
- |
|
| Perceptive Life Sciences Master Fund Ltd |
10% Owner |
– – • |
2016-12-06 |
4 |
B |
$3.05 |
$10,321,063 |
I/I |
3,383,955 |
6,213,314 |
1.5 |
- |
|
| Nelsen Robert |
10% Owner |
– – • |
2015-08-17 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
3,397,830 |
|
- |
|
| Gillis Steven |
Director |
– • • |
2015-08-17 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
3,397,830 |
|
- |
|
| Perceptive Life Sciences Master Fund Ltd |
10% Owner |
– – • |
2015-08-14 |
4 |
B |
$2.08 |
$1,352,000 |
I/I |
650,000 |
3,260,356 |
1.5 |
- |
|
| Gillis Steven |
Director |
– • • |
2015-08-13 |
4 |
A |
$2.10 |
$1,365,000 |
I/I |
650,000 |
4,047,830 |
|
- |
|
| Nelsen Robert |
10% Owner |
– – • |
2015-08-13 |
4 |
A |
$2.10 |
$1,365,000 |
D/D |
650,000 |
4,047,830 |
|
- |
|
| Anderson David Evander |
Senior VP, Researc |
• • – |
2015-04-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(46,731) |
86,787 |
|
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2014-07-25 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
2,610,356 |
|
- |
|
| Anderson David Evander |
Senior Vice Presiden, Research |
• – – |
2014-07-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
133,518 |
|
- |
|
| Buckley T. Adam |
VP, Operations & Project Mgmt. |
• – – |
2014-07-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
41,016 |
|
- |
|
| Nascimento Egidio |
Chief Financial OfficerOfficer |
• – – |
2014-07-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,411 |
|
- |
|
| Gillis Steven |
Director |
– • • |
2014-07-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,399,253 |
|
- |
|
| Gillis Steven |
Director |
– • • |
2014-07-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,541 |
|
- |
|
| Perceptive Life Sciences Master Fund Ltd |
10% Owner |
– – • |
2014-07-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,270,404 |
|
- |
|
| Clarus Lifesciences I, L.p. |
10% Owner |
– – • |
2014-07-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,973,820 |
|
- |
|
| Nelsen Robert |
10% Owner |
– – • |
2014-07-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,399,253 |
|
- |
|
| Shoen Paul F |
See Explanatory Note below |
– – – |
2014-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,778 |
44,155 |
|
- |
|
| Smith Murray George |
See Explanatory Note below |
– – – |
2014-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
35,900 |
|
- |
|
| Davis Trent D |
See Explanatory Note below |
– • – |
2014-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,167 |
64,167 |
|
- |
|
| Paulson Charles |
See Explanatory Note below |
– – – |
2014-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,260 |
34,260 |
|
- |
|
| Shoen Paul F |
Director |
– • – |
2014-04-10 |
4 |
A |
$0.00 |
$0 |
D/D |
26,250 |
206,881 |
|
- |
|
| Paulson Charles |
Director |
– • – |
2014-04-10 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
150,000 |
|
- |
|
174 Records found
|
|
Page 1 of 7 |
|
|
0.03 (4.24%) 
